Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2010, Article ID 458156, 4 pages
http://dx.doi.org/10.1155/2010/458156
Case Report

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis

1Pôle d’Hématologie et d’Oncologie, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France
2Pôle de Biologie, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France
3Service d’Anatomie pathologique, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France
4Service d’Oncologie Médicale, Centre Hospitalier de Chambéry, 73011, France
5Service d’Oncologie Médicale, Centre Hospitalier Universitaire, 31052 Toulouse, France

Received 5 October 2009; Revised 4 January 2010; Accepted 25 January 2010

Academic Editor: Irene Andrulis

Copyright © 2010 Jean-Emmanuel Kurtz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. A. Alman, M. E. Pajerski, S. Diaz-Cano, K. Corboy, and H. J. Wolfe, “Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder,” Diagnostic Molecular Pathology, vol. 6, no. 2, pp. 98–101, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Stoeckle, J. M. Coindre, M. Longy et al., “A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases,” European Journal of Surgical Oncology, vol. 35, no. 2, pp. 129–134, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Duffaud and A. Le Cesne, “Imatinib in the treatment of solid tumours,” Targeted Oncology, vol. 4, no. 1, pp. 45–56, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. C. L. Corless, L. McGreevey, A. Town et al., “KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors,” Journal of Molecular Diagnostics, vol. 6, no. 4, pp. 366–370, 2004. View at Google Scholar · View at Scopus
  5. J. Mace, J. Sybil Biermann, V. Sondak et al., “Response of extraabdominal desmoid tumors to therapy with imatinib mesylate,” Cancer, vol. 95, no. 11, pp. 2373–2379, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Gonçalves, G. Monges, Y. Yang et al., “Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis,” Journal of the National Cancer Institute, vol. 98, no. 8, pp. 562–563, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Wcislo, K. Szarlej-Wcislo, and C. Szczylik, “Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature,” Journal of Cancer Research and Clinical Oncology, vol. 133, no. 8, pp. 533–538, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. C. Heinrich, G. A. McArthur, G. D. Demetri et al., “Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor),” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1195–1203, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Fayette, A. Dufresne, N. Penel et al., “Imatinib for the treatment of aggressive fibromatosis/desmoid tumors (AF/DT) failing local treatment: updated outcome and predictive factors for progression free survival. A FNCLCC French Sarcoma Group-GETO study,” Journal of Clinical Oncology, vol. 25, no. 18, supplement, 2007, abstract no. 10062. View at Google Scholar
  10. J. Seinfeld, B. K. Kleinschmidt-Demasters, S. Tayal, and K. O. Lillehei, “Desmoid-type fibromatoses involving the brachial plexus: treatment options and assessment of c-KIT mutational status,” Journal of Neurosurgery, vol. 104, no. 5, pp. 749–756, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. E. Tamborini, T. Negri, F. Miselli, M. S. Lagonigro, S. Pricl, and S. Pilotti, “Re: response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis,” Journal of the National Cancer Institute, vol. 98, no. 21, pp. 1583–1584, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Bertucci, A. Gonçalves, P. Viens, G. Monges, and P. Dubreuil, “Desmoid-type fibromatosis,” Journal of Neurosurgery, vol. 107, no. 2, pp. 473–475; author reply 475, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Krüger, M. Emig, P. Lohse, G. Ehninger, A. Hochhaus, and H. K. Schackert, “The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians,” Leukemia, vol. 20, no. 2, pp. 354–355, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. X.-Y. Yin, Y.-Q. Ren, S. Yang et al., “A novel KIT missense mutation in one Chinese family with piebaldism,” Archives of Dermatological Research, vol. 301, no. 5, pp. 387–389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Orfao, A. C. Garcia-Montero, L. Sanchez, and L. Escribano, “Recent advances in the understanding of mastocytosis: the role of KIT mutations,” British Journal of Haematology, vol. 138, no. 1, pp. 12–30, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Cammenga, S. Horn, U. Bergholz et al., “Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate,” Blood, vol. 106, no. 12, pp. 3958–3961, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Gari, A. Goodeve, G. Wilson et al., “c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia,” British Journal of Haematology, vol. 105, no. 4, pp. 894–900, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Boissel, H. Leroy, B. Brethon et al., “Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML),” Leukemia, vol. 20, no. 6, pp. 965–970, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Cairoli, A. Beghini, E. Morello et al., “Imatinib mesylate in the treatment of Core Binding Factor leukemia's with KIT mutations: a report of three cases,” Leukemia Research, vol. 29, no. 4, pp. 397–400, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Cortes, F. Giles, S. O'Brien et al., “Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders,” Cancer, vol. 97, no. 11, pp. 2760–2766, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. J. D. Growney, J. J. Clark, J. Adelsperger et al., “Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412,” Blood, vol. 106, no. 2, pp. 721–724, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. K. M. Skubitz, J. C. Manivel, D. R. Clohisy, and J. W. Frolich, “Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 3, pp. 635–640, 2009. View at Publisher · View at Google Scholar · View at Scopus